Shares of Biogen Inc. BIIB inched 0.10% higher to $150.64 Tuesday, on what proved to be an all-around grim trading session ...
Shares of Biogen Inc. BIIB inched 0.31% higher to $150.49 Monday, on what proved to be an all-around mixed trading session ...
Hosted on MSN1d
Biogen Stock: Is BIIB Underperforming the Healthcare Sector?Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, with a market cap of $21.9 billion, is a leading biotechnology ...
Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Medicare Advantage plans must cover Biogen’s (NASDAQ:BIIB) drug Qalsody for the treatment of ALS, according to a report. The ...
Stifel analyst Paul Matteis downgraded Biogen (BIIB) to Hold from Buy with a $175 price target It’s been a challenging year and while there are other reasons that are contributing, it’s “mostly driven ...
In a rare move, the U.S. agency behind Medicare is warning insurers who provide Medicare Advantage plans that they can’t automatically deny coverage of Qalsody, a Biogen drug approved to treat ...
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback